Cyanine3 amine

Cat. #	Quantity	Price	Lead time
110C0	1 mg	$125	in stock
210C0	5 mg	$260	in stock
410C0	25 mg	$510	in stock
510C0	50 mg	$895	in stock
610C0	100 mg	$1490	in stock

Found better price? Let us know and we will propose the way forward!

Cyanine3 amine is a functionalized cyanine dye containing a free amino group. Cyanine3 is an analog of Cy3®.

Amino group of this reagent can be conjugated with reactive groups such as NHS esters, carboxy groups (after carbodiimide activation), and epoxides.

The amino dye is supplied in salt form, and possesses some aqueous solubility.

Cyanine3 absorption and emission spectra

Appearance:	red powder
Molecular weight:	627.73
CAS number:	2247688-56-6
Molecular formula:	C₃₆H₅₂Cl₂N₄O
IUPAC name:	3H-Indolium, 1-[6-[(6-aminohexyl)amino]-6-oxohexyl]-2-[3-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1-propen-1-yl]-3,3-dimethyl-, chloride, hydrochloride (1:1:1)
Solubility:	moderate solubility in water, good in polar organic solvents (DMF, DMSO, alcohols)
Quality control:	NMR ¹H, HPLC-MS (95%)
Storage conditions:	Storage: 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light. Desiccate.
MSDS:	Download
	Product specifications

Excitation/absorption maximum, nm:	555
ε, L⋅mol⁻¹⋅cm⁻¹:	150000
Emission maximum, nm:	570
Fluorescence quantum yield:	0.31
CF₂₆₀:	0.04
CF₂₈₀:	0.09

Lee, J.-R.; Sim, W.-S.; Park, H.-J.; Park, B.-W.; Joung, Y. K. Targeted Delivery of Apoptotic Cell-Derived Nanovesicles Prevents Cardiac Remodeling and Attenuates Cardiac Function Exacerbation. Advanced Functional Materials, 2023, 33(23), 2210864. doi: 10.1002/adfm.202210864
Nizamov, T. R.; Iliasov, A. R.; Vodopyanov, S. S.; Kozhina, I. V.; Bordyuzhin, I. G.; Zhukov, D. G.; Ivanova, A. V.; Permyakova, E. S.; Mogilnikov, P. S.; Vishnevskiy, D. A.; Shchetinin, I. V.; Abakumov, M. A.; Savchenko, A. G. Study of Cytotoxicity and Internalization of Redox-Responsive Iron Oxide Nanoparticles on PC-3 and 4T1 Cancer Cell Lines. Pharmaceutics, 2023, 15(1), 127. doi: 10.3390/pharmaceutics15010127
Malinovskaya, J.; Salami, R.; Valikhov, M.; Vadekhina, V.; Semyonkin, A.; Semkina, A.; Abakumov, M.; Harel, Y.; Levy, E.; Levin, T.; Persky, R.; Chekhonin, V.; Lellouche, J.-P.; Melnikov, P.; Gelperina, S. Supermagnetic Human Serum Albumin (HSA) Nanoparticles and PLGA-Based Doxorubicin Nanoformulation: A Duet for Selective Nanotherapy. International Journal of Molecular Sciences, 2023, 24(1), 627. doi: 10.3390/ijms24010627
Ruan, Z.; Li, S.; Grigoropoulos, A.; Amiri, H.; Hilburg, S. L.; Chen, H.; Jayapurna, I.; Jiang, T.; Gu, Z.; Alexander-Katz, A.; Bustamante, C.; Huang, H.; Xu, T. Population-Based Heteropolymer Design to Mimic Protein Mixtures. Nature, 2023, 615(7951), 251–258. doi: 10.1038/s41586-022-05675-0